 |
|
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
Jun Miyoshi, Katsuyoshi Matsuoka, Atsushi Yoshida, Makoto Naganuma, Tadakazu Hisamatsu, Tomoharu Yajima, Nagamu Inoue, Susumu Okamoto, Yasushi Iwao, Haruhiko Ogata, Fumiaki Ueno, Toshifumi Hibi, Takanori Kanai
Intest Res. 2018;16(4):635-640. Published online 2018 Oct 10 DOI: https://doi.org/10.5217/ir.2018.00015
|
|
Citations to this article as recorded by
 Krill Oil and Its Bioactive Components as a Potential Therapy for Inflammatory Bowel Disease: Insights from In Vivo and In Vitro Studies
Yingying Liu, Ainsley M. Robinson, Xiao Qun Su, Kulmira Nurgali
Biomolecules.2024; 14(4): 447. CrossRef Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
Pediatrics International.2023;[Epub] CrossRef Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
Digestion.2023; 104(1): 58. CrossRef APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease
Lauren Sahakian, Ainsley M. Robinson, Linda Sahakian, Rhian Stavely, Mark R. Kelley, Kulmira Nurgali
Biomolecules.2023; 13(11): 1569. CrossRef
|